BVC:LSE-BATM Advanced Communications Ltd (GBX)

COMMON STOCK | Medical Instruments & Supplies | LSE

Last Closing Price

GBX 100.50

Change

-1.00 (-0.99)%

Market Cap

GBX 0.45B

Volume

0.48M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

BATM Advanced Communications Ltd., together with its subsidiaries, provides real-time technologies for networking solutions and bio-medical systems in Israel, the United States, and Europe. It operates in two divisions, Networking and Cyber, and Bio-Medical. The Networking and Cyber division is involved in the research and development, production, and marketing of data communication products, including network function virtualization in the fields of local and wide area networks, and premises management systems. This division provides ICT solutions and services; and cyber security solutions. It also offers software services, such as training, technical support and maintenance related to the communication products, mobile and Web solutions, UI, UX design, branding, graphical design, and drivers and embedded solutions; and construction contracts. The Bio-Medical division engages in the research and development, production, marketing, and distribution of medical products, such as laboratory diagnostics and sterilization equipment. This division offers molecular biology diagnostics; provides solutions to treat pathogenic and medical waste in laboratories and hospitals, as well as for pharmaceutical manufacturing plants and agricultural applications; and distributes diagnostic equipment and medical supplies of various brands. BATM Advanced Communications Ltd. has a collaboration with Novamed Ltd for the joint development and marketing of a home-use testing kit for COVID-19. The company was founded in 1992 and is headquartered in Hod Hasharon, Israel.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-04 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CTEC:LSE Convatec Group Plc

+2.60 (+1.40%)

GBX3.73B 155.17 15.55
AMS:LSE Advanced Medical Solutions Gro..

+1.50 (+0.67%)

GBX0.48B 35.71 18.64
TSTL:LSE Tristel plc

-15.00 (-2.44%)

GBX0.29B 54.91 27.75
ODX:LSE Omega Diagnostics Group PLC

-0.50 (-0.56%)

GBX0.16B 16.43 106.33

ETFs Containing BVC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.06% 60% D- 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.06% 60% D- 73% C
Trailing 12 Months  
Capital Gain 125.84% 80% B- 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 125.84% 80% B- 94% A
Trailing 5 Years  
Capital Gain 523.26% 100% A+ 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 523.26% 100% A+ 96% A
Average Annual (5 Year Horizon)  
Capital Gain 61.55% 80% B- 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 61.55% 80% B- 89% B+
Risk Return Profile  
Volatility (Standard Deviation) 57.14% 40% F 20% F
Risk Adjusted Return 107.71% 80% B- 92% A-
Market Capitalization 0.45B 60% D- 68% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 46.14 60% D- 20% F
Price/Book Ratio 6.45 60% D- 15% F
Price / Cash Flow Ratio 24.22 60% D- 19% F
EV/EBITDA 39.01 40% F 12% F
Management Effectiveness  
Return on Equity 10.29% 80% B- 75% C
Return on Invested Capital 10.81% 40% F 74% C
Return on Assets 4.56% 60% D- 75% C
Debt to Equity Ratio 0.55% 75% C 91% A-
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.19 100% A+ 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.